Farnesoid X receptor (FXR) as a potential therapeutic target in nonalcoholic fatty liver disease and associated syndromes

Nonalcoholic fatty liver disease (NAFLD) is a group of obesity-associated pathological changes characterized by abnormal accumulation of lipids in cells of the liver parenchyma. NAFLD and associated conditions, namely insulin resistance and type II diabetes mellitus (DM2), as well as the possible ri...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Apollinariya V. Bogolyubova, Alexander Y. Mayorov, Ekaterina E. Mishina, Anton M. Schwartz, Pavel V. Belousov
Formato:	article
Lenguaje:	EN RU
Publicado:	Endocrinology Research Centre 2017
Materias:	nonalcoholic fatty liver disease nonalcoholic steatohepatitis farnesoid x Nutritional diseases. Deficiency diseases RC620-627
Acceso en línea:	https://doaj.org/article/d30df532fce74d6d8dfcbb518f2a4ae4
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:d30df532fce74d6d8dfcbb518f2a4ae4
record_format	dspace
spelling	oai:doaj.org-article:d30df532fce74d6d8dfcbb518f2a4ae42021-11-14T09:00:21ZFarnesoid X receptor (FXR) as a potential therapeutic target in nonalcoholic fatty liver disease and associated syndromes2072-03512072-037810.14341/DM9374https://doaj.org/article/d30df532fce74d6d8dfcbb518f2a4ae42017-12-01T00:00:00Zhttps://www.dia-endojournals.ru/jour/article/view/9374https://doaj.org/toc/2072-0351https://doaj.org/toc/2072-0378Nonalcoholic fatty liver disease (NAFLD) is a group of obesity-associated pathological changes characterized by abnormal accumulation of lipids in cells of the liver parenchyma. NAFLD and associated conditions, namely insulin resistance and type II diabetes mellitus (DM2), as well as the possible risks of developing fibrosis and cirrhosis with a potential outcome in hepatocellular carcinoma, represent the primary health problems in developed countries, gradually replacing the importance of similar pathologies caused by the regular use of hepatotoxic doses of alcoholic beverages. Recent fundamental and clinical studies demonstrated the important role of the farnesoid receptor (FXR, NR1H4) in the regulation of the metabolism of glucose, lipids and bile acids. This review focuses on the molecular aspects of the pathogenesis of NAFLD, the role of FXR (NR1H4) in the biology of this disease, and the prospects for using different FXR (NR1H4) modulators for therapy of NAFLD and associated conditions such as metabolic syndrome and DM2, as well as a number of other FXR (NR1H4) – mediated diseases.Apollinariya V. BogolyubovaAlexander Y. MayorovEkaterina E. MishinaAnton M. SchwartzPavel V. BelousovEndocrinology Research Centrearticlenonalcoholic fatty liver diseasenonalcoholic steatohepatitisfarnesoid xNutritional diseases. Deficiency diseasesRC620-627ENRUСахарный диабет, Vol 20, Iss 6, Pp 449-453 (2017)
institution	DOAJ
collection	DOAJ
language	EN RU
topic	nonalcoholic fatty liver disease nonalcoholic steatohepatitis farnesoid x Nutritional diseases. Deficiency diseases RC620-627
spellingShingle	nonalcoholic fatty liver disease nonalcoholic steatohepatitis farnesoid x Nutritional diseases. Deficiency diseases RC620-627 Apollinariya V. Bogolyubova Alexander Y. Mayorov Ekaterina E. Mishina Anton M. Schwartz Pavel V. Belousov Farnesoid X receptor (FXR) as a potential therapeutic target in nonalcoholic fatty liver disease and associated syndromes
description	Nonalcoholic fatty liver disease (NAFLD) is a group of obesity-associated pathological changes characterized by abnormal accumulation of lipids in cells of the liver parenchyma. NAFLD and associated conditions, namely insulin resistance and type II diabetes mellitus (DM2), as well as the possible risks of developing fibrosis and cirrhosis with a potential outcome in hepatocellular carcinoma, represent the primary health problems in developed countries, gradually replacing the importance of similar pathologies caused by the regular use of hepatotoxic doses of alcoholic beverages. Recent fundamental and clinical studies demonstrated the important role of the farnesoid receptor (FXR, NR1H4) in the regulation of the metabolism of glucose, lipids and bile acids. This review focuses on the molecular aspects of the pathogenesis of NAFLD, the role of FXR (NR1H4) in the biology of this disease, and the prospects for using different FXR (NR1H4) modulators for therapy of NAFLD and associated conditions such as metabolic syndrome and DM2, as well as a number of other FXR (NR1H4) – mediated diseases.
format	article
author	Apollinariya V. Bogolyubova Alexander Y. Mayorov Ekaterina E. Mishina Anton M. Schwartz Pavel V. Belousov
author_facet	Apollinariya V. Bogolyubova Alexander Y. Mayorov Ekaterina E. Mishina Anton M. Schwartz Pavel V. Belousov
author_sort	Apollinariya V. Bogolyubova
title	Farnesoid X receptor (FXR) as a potential therapeutic target in nonalcoholic fatty liver disease and associated syndromes
title_short	Farnesoid X receptor (FXR) as a potential therapeutic target in nonalcoholic fatty liver disease and associated syndromes
title_full	Farnesoid X receptor (FXR) as a potential therapeutic target in nonalcoholic fatty liver disease and associated syndromes
title_fullStr	Farnesoid X receptor (FXR) as a potential therapeutic target in nonalcoholic fatty liver disease and associated syndromes
title_full_unstemmed	Farnesoid X receptor (FXR) as a potential therapeutic target in nonalcoholic fatty liver disease and associated syndromes
title_sort	farnesoid x receptor (fxr) as a potential therapeutic target in nonalcoholic fatty liver disease and associated syndromes
publisher	Endocrinology Research Centre
publishDate	2017
url	https://doaj.org/article/d30df532fce74d6d8dfcbb518f2a4ae4
work_keys_str_mv	AT apollinariyavbogolyubova farnesoidxreceptorfxrasapotentialtherapeutictargetinnonalcoholicfattyliverdiseaseandassociatedsyndromes AT alexanderymayorov farnesoidxreceptorfxrasapotentialtherapeutictargetinnonalcoholicfattyliverdiseaseandassociatedsyndromes AT ekaterinaemishina farnesoidxreceptorfxrasapotentialtherapeutictargetinnonalcoholicfattyliverdiseaseandassociatedsyndromes AT antonmschwartz farnesoidxreceptorfxrasapotentialtherapeutictargetinnonalcoholicfattyliverdiseaseandassociatedsyndromes AT pavelvbelousov farnesoidxreceptorfxrasapotentialtherapeutictargetinnonalcoholicfattyliverdiseaseandassociatedsyndromes
_version_	1718429557267103744

Farnesoid X receptor (FXR) as a potential therapeutic target in nonalcoholic fatty liver disease and associated syndromes

Ejemplares similares